GTCBio vaccine conference offers updates on biodefense policies

WASHINGTON, D.C. — GTCbio’s seventh annual Vaccines: All Things Considered conference is scheduled for Nov 9-10 in Washington.

This conference promises to be the one-stop destination for valuable updates and exposure on all aspects of vaccine research, development, regulations and policy. The research and discovery of vaccines to fight globally prevalent diseases has been a major focus of the pharmaceutical industry’s biggest players for decades.

The pharmaceutical world has recently been rocked by the pending expiration of patents on several major blockbuster drugs. How does this affect funding for vaccine research and development? What will be the path forward? How will the generic drug industry affect the vaccines market? These are just a few of the questions the Vaccines conference will address and answer.

Recent advances in the discovery of novel vaccines that target not only traditional infectious diseases (such as malaria, influenza, AIDS, meningitis, etc), but non-infectious diseases (such as cancer, allergies and even smoking) as well, prove to be both innovative and promising for the industry.

The vaccines conference is the perfect forum to network with colleagues and gain valuable information on these exciting next generation vaccines. ??In the spirit of truly considering all things, GTCbio’s vaccines conference also brings together leading government officials, such as representatives from the Department of Health and Human Services and the Food and Drug Administration, to provide a first-hand perspective into current U.S. vaccines policy and regulation.

Updates on the pandemic and biodefense policy as well as the National Vaccine Plan will be addressed and discussed.

GTCbio organizes conferences, workshops, training courses and tradeshows specifically for the biomedical and biopharmaceutical industries. GTCbio is a subsidiary of Global Technology Community, a privately held company founded in 2002.